Limits...
Increased homocysteine levels in valproate-treated patients with epilepsy: a meta-analysis.

Ni G, Qin J, Fang Z, Chen Y, Chen Z, Zhou J, Zhou L - BMJ Open (2014)

Bottom Line: Pooled standardised mean difference (SMD) and 95% CIs were calculated using a random effect model.There was significant heterogeneity in the estimates according to the I(2) test (I(2)=65.6%, p=0.005).Further subgroup analyses suggested that no significant differences were present when grouped by ethnicity and age, but the risk of heterogeneity in the West Asian group (I(2)=47.4%, p=0.107) was diminished when compared with that of the overall group (I(2)=65.6%, p=0.005).

View Article: PubMed Central - PubMed

Affiliation: Department of Neurology, Epilepsy Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong Province, China.

No MeSH data available.


Related in: MedlinePlus

Search strategy for meta-analysis.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4120332&req=5

BMJOPEN2014004936F1: Search strategy for meta-analysis.

Mentions: In line with our research strategy, a total of 30 potentially relevant researches were identified in our initial literature search. Finally, our research enrolled eight eligible studies that met the inclusion criteria.1–4710–12 A flow chart showing the study selection is presented in figure 1. The characteristics of eligible studies including VPA therapeutic dosage, duration of VPA monotherapy and plasma homocysteine concentrations (mean±SD) are listed in table 1, which involved 266 patients with epilepsy receiving VPA monotherapy and 489 healthy controls.


Increased homocysteine levels in valproate-treated patients with epilepsy: a meta-analysis.

Ni G, Qin J, Fang Z, Chen Y, Chen Z, Zhou J, Zhou L - BMJ Open (2014)

Search strategy for meta-analysis.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4120332&req=5

BMJOPEN2014004936F1: Search strategy for meta-analysis.
Mentions: In line with our research strategy, a total of 30 potentially relevant researches were identified in our initial literature search. Finally, our research enrolled eight eligible studies that met the inclusion criteria.1–4710–12 A flow chart showing the study selection is presented in figure 1. The characteristics of eligible studies including VPA therapeutic dosage, duration of VPA monotherapy and plasma homocysteine concentrations (mean±SD) are listed in table 1, which involved 266 patients with epilepsy receiving VPA monotherapy and 489 healthy controls.

Bottom Line: Pooled standardised mean difference (SMD) and 95% CIs were calculated using a random effect model.There was significant heterogeneity in the estimates according to the I(2) test (I(2)=65.6%, p=0.005).Further subgroup analyses suggested that no significant differences were present when grouped by ethnicity and age, but the risk of heterogeneity in the West Asian group (I(2)=47.4%, p=0.107) was diminished when compared with that of the overall group (I(2)=65.6%, p=0.005).

View Article: PubMed Central - PubMed

Affiliation: Department of Neurology, Epilepsy Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong Province, China.

No MeSH data available.


Related in: MedlinePlus